CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Passos, S.
Right arrow Articles by Carvalho, E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Passos, S.
Right arrow Articles by Carvalho, E. M.
Clinical and Diagnostic Laboratory Immunology, October 2005, p. 1164-1167, Vol. 12, No. 10
1071-412X/05/$08.00+0     doi:10.1128/CDLI.12.10.1164-1167.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Recombinant Leishmania Antigens for Serodiagnosis of Visceral Leishmaniasis

S. Passos,1 L. P. Carvalho,1 G. Orge,1 S. M. Jerônimo,2 G. Bezerra,3 M. Soto,4 C. Alonso,4 and E. M. Carvalho1*

Serviço de Imunologia, Hospital Universitário Prof. Edgard Santos, Universidade Federal da Bahia, Salvador, Bahia, Brazil,1 Laboratório de Imunobioquímica, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil,2 Centro de Ciências Biológicas e da Saúde, Universidade Federal do Maranhão, São Luís, Maranhão, Brazil,3 Centro de Biologia Molecular Severo Ochoa, Faculdad de Ciencias, Universidad de Madrid, Madrid, Spain4

Received 5 May 2005/ Returned for modification 13 June 2005/ Accepted 9 August 2005

Serological tests with crude or recombinant Leishmania antigens are important tools for the diagnosis of leishmania infection. However, these tests are not markers of active visceral leishmaniasis (VL), since antibodies to these markers are often observed in individuals with subclinical L. chagasi infection and they do not fall shortly after therapy. In this study, levels of immunoglobulin G (IgG) against three recombinant Leishmania antigens (rH2A, KMP11, and the "Q" protein) were evaluated in sera from individuals with subclinical L. chagasi infection and in patients with VL pre- and posttherapy. The sensitivity of the serological test for diagnosis of VL was 100% with all three antigens. The titers of IgG fell significantly after therapy. While most of the individuals with subclinical L. chagasi infection had antibodies to rH2A and the "Q" protein, only 1 out of 15 individuals had antibodies to KMP11. These data indicate that KMP11 may be used to discriminate L. chagasi infection from active VL and may serve as a marker of response to therapy.

* Corresponding author. Mailing address: Hospital Universitário Professor Edgard Santos, Serviço de Imunologia, 5 andar, Rua João das Botas, s/n Canela, 40110-160, Salvador, Bahia, Brazil. Phone: (55.71) 3237-7353. Fax: (55.71) 3245-7110. E-mail: edgar{at}ufba.br.

Clinical and Diagnostic Laboratory Immunology, October 2005, p. 1164-1167, Vol. 12, No. 10
1071-412X/05/$08.00+0     doi:10.1128/CDLI.12.10.1164-1167.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2005 by the American Society for Microbiology. All rights reserved.